Cambridge Antibody Technology (CATGY) Inactive
Filed: 7 Jun 06, 12:00am
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
7 June, 2006
Cambridge Antibody Technology Group PLC
(Translation of Registrant’s Name Into English)
Milstein Building, Granta Park, Cambridge, CB1 6GH, England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-
Form 20-F ____X____ Form 40-F ________
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2 (b) under the Securities Exchange Act of 193
Yes _________ No ____X_____
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2 (b): 82-___________
EXHIBIT INDEX
This filing contains the following exhibits.
EXHIBIT DESCRIPTION
99.1 Holding(s) in Company, 7th of June, 2006
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: 7 June, 2006 Cambridge Antibody Technology Group PLC
By: /s/ John Aston
Name: John Aston
Title: Chief Financial Officer
EXHIBIT 99.1
NOTIFICATION OF MAJOR INTERESTS IN SHARES
1. Name of company
Cambridge Antibody Technology Group plc
2. Name of shareholder having a major interest
The Goldman Sachs Group Inc.
3. Please state whether notification indicates that it is in respect of holding of the shareholder named in 2 above or in respect of
a non-beneficial interest or in the case of an individual holder if it is a holding of that person's spouse or children under the age
of 18
Not disclosed
4. Name of the registered holder(s) and, if more than one holder, the number of shares held by each of them
Not disclosed
5. Number of shares / amount of stock acquired
not disclosed
6. Percentage of issued class
not known
7. Number of shares / amount of stock disposed
not known
8. Percentage of issued class
not known
9. Class of security
Ordinary 10 pence shares
10. Date of transaction
not disclosed
11. Date company informed
6 June 2006
12. Total holding following this notification
not disclosed
13. Total percentage holding of issued class following this notification
not known
14. Any additional information
The Goldman Sachs Group inc. no longer has a disclosable interest in shares in Cambridge Antibody Technology Group plc
15. Name of contact and telephone number for queries
Justin Hoskins 01223 898589
16. Name and signature of authorised company official responsible for making this notification
Justin Hoskins, Company Secretary
Date of notification
7 June 2006
The FSA does not give any express or implied warranty as to the accuracy of this document or material and does not accept any
liability for error or omission. The FSA is not liable for any damages (including, without limitation, damages for loss of business
or loss of profits) arising in contract, tort or otherwise from the use of or inability to use this document, or any material
contained in it, or from any action or decision taken as a result of using this document or any such material.
END